The IMS Institute is now the
for Human Data Science
- Institute
- Reports
Stay connected to the IQVIA Institute for publication updates.
Reports
Featured Report
Orphan Drugs in the United States (Part two)
Recent legislative discussion has focused on whether the ODA development incentives are working as intended or being manipulated for commercial gain. This report is a companion analysis to an examination of the orphan drug market published by the IQVIA Institute in October 2018, “Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments,” and sheds new light on this topic with information on the sequence of orphan drugs’ orphan and non-orphan indication approvals and their associated patent and market exclusivities.